Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Total Non-Current Liabilities (2017 - 2022)

Historic Total Non-Current Liabilities for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to $37.7 million.

  • Iterum Therapeutics' Total Non-Current Liabilities fell 1095.69% to $37.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $37.7 million, marking a year-over-year decrease of 1095.69%. This contributed to the annual value of $37.8 million for FY2021, which is 5120.63% down from last year.
  • As of Q3 2022, Iterum Therapeutics' Total Non-Current Liabilities stood at $37.7 million, which was down 1095.69% from $31.1 million recorded in Q2 2022.
  • Over the past 5 years, Iterum Therapeutics' Total Non-Current Liabilities peaked at $78.7 million during Q1 2021, and registered a low of $22.6 million during Q3 2018.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $40.7 million (2019), whereas its average is $47.4 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 25500.98% in 2018, then tumbled by 5909.71% in 2022.
  • Iterum Therapeutics' Total Non-Current Liabilities (Quarter) stood at $25.3 million in 2018, then surged by 76.34% to $44.6 million in 2019, then soared by 73.83% to $77.5 million in 2020, then plummeted by 51.21% to $37.8 million in 2021, then dropped by 0.3% to $37.7 million in 2022.
  • Its Total Non-Current Liabilities was $37.7 million in Q3 2022, compared to $31.1 million in Q2 2022 and $32.2 million in Q1 2022.